Skip to content
‹ Back to IndustriesSciences

How Are AI Pros Weighing ChatGPT’s Role in the World of Science?

New evolving and fast-developing AIs have started rising to fame in recent years, and with the recent invention of ChatGPT – an AI chatbot launched in late 2022 which gained over 100 million users within the first two months of launching – people from all around the world are starting to question the role of AI technology…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · AiChat GptDeveloping AiScience
Share

Key takeaways

01

New evolving and fast-developing AIs have started rising to fame in recent years, and with the recent invention of ChatGPT – an AI chatbot launched in late 2022 which gained over 100 million users within the first two months of launching – people from all around the world are starting to question the role of AI technology…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

New evolving and fast-developing AIs have started rising to fame in recent years, and with the recent invention of ChatGPT – an AI chatbot launched in late 2022 which gained over 100 million users within the first two months of launching – people from all around the world are starting to question the role of AI technology in their daily lives. Among these uncertainties is ChatGPT’s role in the world of science.

Will there be a huge impact of ChatGPT and developing AI in science? How will Chat GPT and developing AI contribute to modern science?

Biologists like Casey Greene and Milton Pividori see the tool as incredibly useful. After running their own research of using the tool for improving the quality and readability of academic manuscripts, Pividori concluded that ChatGPT, alongside other AI tools, is adding value to their lives by making helping scientists be “more productive as researchers.”

Meanwhile, other scientists are saying that they now regularly use LLMs (large language models like ChatGPT) not only to edit manuscripts but also to help them write or check code and to brainstorm ideas. As Nature.com reports, scientists like Almira Osmanovic Thunström, a neurobiologist at Sahlgrenska University Hospital in Gothenburg, says the use of ChatGPT will keep scientists from needing to “sit and write long introductions for grant applications.”

That being said, many scientists and researchers have pointed out a few disadvantages of AI tools. These are in the form of inaccurate information and fictitious citations presented by AI machines, giving scientists a reason to rely less on AI and more on their own manual research and cross-referencing. Can researchers confidently pinpoint ChatGPT’s role in the world of science?

Ganesh Gopalan, CEO and co-founder of Gnani.ai, a conversational AI platform with a focus on customer experience enhancement, weighs in on the impact of ChatGPT and other developing AI tools in the world of science and the difference it can make in research fields.

Ganesh Gopalan’s Thoughts

“ChatGPT is going to help researchers automate all their routine activities such as writing publications, reviewing documents are automatically creating extracts.

These articles typically warn of the pitfalls in terms of biases that ChatGPT could throw up and the possible inaccuracies. So, what I thought the best thing to evaluate this is to ask ChatGPT the same question. When I ask ChatGPT the same questions, I got a lot more results such as the influence on drug discovery, the influence on analyzing large pieces of scientific data and finding the relationships.

So essentially, I guess ChatGPT has a lot of benefits for science but you’ve gotta be a little careful on the biases and also on the accuracy of the data.”

Article written by Azam Saghir.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

C
carey.scott
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Clinical data harmonization is the bottleneck for life sciences AI

Clinical data harmonization is the bottleneck for life sciences AI

Life sciences companies moving AI from experimentation to scale keep running into messy trial data. One study can draw on EDC, health records, eCOA tools, wearables and imaging, and data teams at pharma SMEs often spend up to 80% of their time wrangling it. Commentators point to lakehouse architectures and data-cleansing AI agents, though the agents are still at proof of concept.

  • 01Treat automation gains as proof-of-concept for now; evaluate AI/harmonization choices based on data readiness, governance, and whether the architecture supports traceability and regulatory needs.

Sep 26, 2026

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

Contract Pharma reports bioTRAK data projecting CDMOs will install roughly 120 bioreactors by 2030. It says 71% of added volume is large-scale stainless steel, while 61% of systems are single-use.

  • 01Utilization discipline is still driving builds: BioTRAK’s Dawn Ecker told Contract Pharma expansion conversations typically start after a site is booked above ~80% for several years.

Sep 22, 2026

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512